hábit Labs · Devolve Corp
Certificate of Analysis
FOR RESEARCH PURPOSES ONLY. This material is supplied for in-vitro laboratory research by qualified researchers. It shall not be used for human therapeutic purposes and is not for human or veterinary consumption. It is not a drug, supplement, cosmetic, food additive, or medical device.
Product identification
ProductRetatrutide 20mg
DescriptionTriple GIP/GLP-1/glucagon receptor agonist
Lot numberRET-2606-A
Release dateJun 2026
Molecular formula—
AppearanceLyophilized powder
Storage−20 °C, protected from light
ManufacturerDevolve Corp d/b/a hábit · Ft. Lauderdale, FL
Analytical results
Identity (LC-MS)Confirmed✓ Pass
Purity (HPLC)99.1%✓ Pass
Mass spec (MW)≈4,731✓ Pass
Endotoxin (LAL)<0.5 EU/mg✓ Pass
Residual solventsWithin spec✓ Pass
AppearanceWhite cake✓ Pass
Each Retatrutide vial ships with a batch-specific COA: peptide identity by LC-MS, purity by reverse-phase HPLC (≥99%), mass spec confirmation, endotoxin by LAL, residual solvent screening, and appearance. Third-party ISO-17025 verification.
Specifications
CAS2381089-83-2
Molecular weight≈4,731 g/mol
FormLyophilized, sealed under nitrogen
Purity≥99% by HPLC, mass spec single peak
Endotoxin<0.5 EU/mg
Available dosages20mg / 60mg
Lot prefixRET-
Storage & handling
Lyophilized: −20°C, 24 months unopened. Reconstituted: 2–8°C, use within 30 days. Reconstitute with bacteriostatic water; swirl, do not shake. Avoid repeated freeze-thaw.